Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Return on Sales (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Return on Sales for 3 consecutive years, with 120.31% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 37727.0% to 120.31% in Q3 2025 year-over-year; TTM through Sep 2025 was 120.31%, a 37727.0% increase, with the full-year FY2024 number at 8437.86%, up 857104.0% from a year prior.
  • Return on Sales was 120.31% for Q3 2025 at Inhibrx Biosciences, up from 22.04% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 18580.11% in Q2 2024 to a low of 1297.5% in Q2 2023.
  • A 3-year average of 1662.11% and a median of 7.84% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: soared 1987761bps in 2024, then tumbled -1860215bps in 2025.
  • Inhibrx Biosciences' Return on Sales stood at 56.29% in 2023, then tumbled by -750bps to 478.65% in 2024, then soared by 125bps to 120.31% in 2025.
  • Per Business Quant, the three most recent readings for INBX's Return on Sales are 120.31% (Q3 2025), 22.04% (Q2 2025), and 16.11% (Q1 2025).